TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21030704
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drugs (used as additional treatment of fever)
Study: 15882239
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor-start (omeprazole 20 mg daily for 4-8 weeks, then stepped up to omeprazole 40 or 20 mg daily for persistent symptoms)
Study: 15882239
Drug: H2-receptor antagonist-start
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H2-receptor antagonist-start (ranitidine 150 mg bid for 4-8 weeks, then stepped up to omeprazole for persistent symptoms)
Study: 15882239
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor-start
Study: 15882239
Drug: H2-receptor antagonist-start
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H2-receptor antagonist-start
Study: 10421666
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg orally daily for 12 months
Study: 30212814
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of clear liquids (Group A)
Study: 30212814
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of PEG (Group B)
Study: 30212814
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of PEG (Group C)
Study: 16923230
Drug: Pea-fibre/FOS formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea-fibre/FOS formula (10 g/l pea-fibre and 5 g/l fructo-oligosaccharides)
Study: 12893078
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5mg once daily for 1 year
Study: 10851374
Drug: Lamotrigine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (300 mg per day after titration from 25 mg per day over 7 weeks)
Study: 22588927
Drug: High-dose ATG-F
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATG-F (30 mg/kg)
Study: 22588927
Drug: Low-dose ATG-F
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATG-F (15 mg/kg)
Study: 18175750
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose (64 g)
Study: 18175750
Drug: Intraduodenal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal protein (72 g whey)
Study: 10423464
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin plus amoxicillin-clavulanate
Study: 7589769
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (500 mg/kg)
Study: 1979923
Drug: IV dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of 25 mg
Study: 1979923
Drug: IV dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose of 5 mg to 20 mg
Study: 1979923
Drug: IV dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose
Study: 1979923
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: 6928953
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group I) received no oral hygiene lectures or instructions until the conclusion of the experiment.
Study: 31089805
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration anesthesia (L)
Study: 25175985
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (performing functional movement synergies using the unaffected forearm, wrist, and hand)
Study: 21159375
Drug: Collaborative stepped-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative stepped-care intervention led by lay health counsellors, supplemented by antidepressant drugs; duration: 6 months
Study: 20834044
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 mg)
Study: 9474309
Drug: Silicone lens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone lens implants
Study: 9474309
Drug: PMMA lens
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMMA lens implants
Study: 9272403
Drug: Moxonidine 0.4
Normalized name: moxonidine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.4 mg once daily
Study: 7533223
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of moxonidine 0.4 mg and hydrochlorothiazide 25 mg
Study: 26508680
Drug: Levocarnitine therapy
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine therapy (20mg/kg/d for 12 months)
Study: 26508680
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no levocarnitine therapy)
Study: 26508680
Drug: Levocarnitine therapy
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocarnitine therapy
Study: 22683042
Drug: ERN/LRPT 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT 1 g/20 mg/day from 0 to 4 weeks and then ERN/LRPT 2 g/40 mg/day from 5 to 32 weeks
Study: 22683042
Drug: ERN 2
Normalized name: ALLERGENIC EXTRACT, 3 GRASS, SOUTHERN 20000PNU/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN 2 g/day without LRPT from 21 to 32 weeks
Study: 20725588
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IG; Lantus)
Study: 20725588
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (ID; Levemir)
Study: 18523643
Drug: bivalent killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bivalent killed whole cell oral cholera vaccine
Study: 18523643
Drug: placebo (killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (killed oral Escherichia coli K12)
Study: 10872536
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue insulin aspart (IAsp) administered 15 min after the meal (IAsp(+15min))
Study: 10872536
Drug: Soluble human
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble human insulin (HI) administered immediately before the meal (HI(0min))
Study: 10872536
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue insulin aspart (IAsp) administered immediately before the meal (IAsp(0min))
Study: 10872536
Drug: Soluble human
Normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble human insulin (HI) administered 15 min before the meal (HI(-15min))
Study: 9117225
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone agonist triptorelin for 3 months before radical prostatectomy (group I)
Study: 9117225
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior therapy (group II)
Study: 3947710
Drug: Naltrexone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (300 mg/day)
Study: 3244786
Drug: Anesthetic therapy
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic therapy with isoflurane
Study: 30501974
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with rhTSH
Study: 30501974
Drug: Preparation with
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation with thyroid hormone withdrawal
Study: 29087285
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2 grams 24 hours and 2 hours preoperatively, 1 gram twice daily for five days post-surgery)
Study: 28229457
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide injection
Study: 21656472
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water injection (Control)
Study: 19351224
Drug: Rasburicase (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasburicase (4.5 mg in 100-cc physiological solution)
Study: 15328495
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological solution)
Study: 22971742
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional medication)
Study: 14993085
Drug: Combination (autodialer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (autodialer with outreach backup)
Study: 11564911
Drug: Alcohol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.7 g/kg body mass)
Study: 11564911
Drug: Alcohol-free solution
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol-free solution
Study: 8500311
Drug: Smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking intervention and use of an inhaled bronchodilator
Study: 27051670
Drug: Vitamin B-6
Normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-6 50 mg/d for 12 weeks
Study: 23659494
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g/day) + Vitamin E (400 IU/day)
Study: 16649826
Drug: Lamotrigine (added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (added to existing therapy)
Study: 14663655
Drug: Rivastigmine or
Normalized name: rivastigmine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine or donepezil (acetylcholinesterase inhibitors)
Study: 23819250
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine
Study: 8546117
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (oral and transdermal)
Study: 2525397
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy
Study: 7173304
Drug: slow-release indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow-release indomethacin tablet
Study: 7173304
Drug: conventional indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional indomethacin capsule
Study: 29862649
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) after 6 months
Study: 29862649
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) of insulin
Study: 29862649
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to CSII therapy
Study: 25440307
Drug: Child- and
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child- and family-focused cognitive-behavioral therapy (CFF-CBT)
Study: 18507735
Drug: Dextromethorphan (DEX)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DEX) at 480 mg/day for 5 weeks
Study: 14764127
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg once daily
Study: 15638900
Drug: Solifenacin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (both doses pooled)
Study: 11856090
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily, clarithromycin 250 mg twice daily, and metronidazole 500 mg twice daily (LCM group)
Study: 11856090
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily (LCA group)
Study: 10208193
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium bromide (42 microg qid) and albuterol sulfate (240 microg qid)
Study: 10208193
Drug: Albuterol base
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol base (180 microg qid)
Study: 8581377
Drug: BIS‐1 F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS‐1 F(ab')2 at doses of 1, 3, or 5 micrograms/kg body weight during concomitantly applied subcutaneous IL‐2 treatment
Study: 8581377
Drug: BIS‐1 F(ab')2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS‐1 F(ab')2 at doses of 3 and 5 micrograms/kg
Study: 2564912
Drug: 0.5% podofilox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podofilox applied by patients to their own genital warts in up to four treatment cycles
Study: 1052
Drug: placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (physiological saline solution)
Study: 22118824
Drug: No Warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Warfarin (Control)
Study: 20688020
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 3 ml of 0.5% bupivacaine for 5 minutes
Study: 19346952
Drug: No miglustat
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No miglustat treatment (Control)
Study: 12867383
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy at a drug dose of 6 mg/m(2) body surface area and a light dose of 50 J/cm(2)
Study: 12867383
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with placebo infusion and light exposure
Study: 10344660
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of atovaquone (7 daily doses)
Study: 10344660
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of atovaquone (single dose)
Study: 1824651
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean dose at 3 years, 5.2 mg/day)
Study: 1824651
Drug: Atenolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (mean dose, 66.4 mg/day)
Study: 6346595
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg ALG administered daily for 10 days by intravenous infusion
Study: 6346595
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered daily for 10 days by intravenous infusion
Study: 16295781
Drug: CY 4
Normalized name: Methenamine/Methylene Blue/Benzoic/Phenyl Sal/Atropin/Hyoscy 40.8 mg-5.4 mg-4.5 mg-18.1 mg-0.03 mg-0.03 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY 4 g/m2 plus lenograstim (arm A)
Study: 16295781
Drug: CY 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY 1.5 g/m2 plus lenograstim (arm B)
Study: 1827344
Drug: 0.1% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% w/w CD 271 alcoholic gel
Study: 1827344
Drug: 0.025% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% w/w tretinoin gel
Study: 1827344
Drug: 0.03% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% w/w CD 271 alcoholic gel
Study: 7313587
Drug: Metronidazole 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 2.0 g on 2 consecutive days
Study: 7313587
Drug: Tinidazole 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2.0 g as a single dose
Study: 7313587
Drug: Metronidazole 200
Normalized name: metronidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 200 mg 3 times daily for 1 week
Study: 30870364
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone (62.5 mg/mL)
Study: 30870364
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin (40 mg/mL)
Study: 22892021
Drug: 10-g Semmes-Weinstein
Normalized name: lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-g Semmes-Weinstein monofilament (SWF) test
Study: 23330199
Drug: Encephabol (suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encephabol (suspension form, daily dosage 200‐250 mg, or 12‐15 mg/kg) for 2 months
Study: 16015691
Drug: Itopride 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 100 mg t.i.d.
Study: 17300287
Drug: Itopride 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 200 mg t.i.d.
Study: 11589257
Drug: parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib sodium (10 mg BID)
Study: 11589257
Drug: ketorolac (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac (15 mg QID)
Study: 9433424
Drug: Phenobarbital (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily)
Study: 9433424
Drug: Phenytoin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (2.5 mg/kg daily then 5.0 mg/kg daily)
Study: 16765182
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG therapy
Study: 30593457
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG ± intradermal HS-410 therapy
Study: 25468282
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual care with routine hemodialysis treatment)
Study: 22833377
Drug: Iguratimod (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iguratimod (25 mg/day for the first 4 weeks, then 50 mg/day for the subsequent 20 weeks) with MTX (6 or 8 mg/week)
Study: 22833377
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with MTX (6 or 8 mg/week)
Study: 21031342
Drug: Protease-inhibitor-modulating-matrix (ORC/collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease-inhibitor-modulating-matrix (ORC/collagen matrix) changed daily
Study: 19387178
Drug: Epidural etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Epidural etanercept 2 mg
Study: 19387178
Drug: Epidural etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Epidural etanercept 4 mg
Study: 19387178
Drug: Epidural etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Epidural etanercept 6 mg
Study: 17979587
Drug: Once-daily multilayer-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily multilayer-release methylphenidate (MLR) at a stable dose of 32.0 mg
Study: 17979587
Drug: Twice-daily immediate-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily immediate-release methylphenidate (IR-MPH) at a stable dose of 32.5 mg
Study: 11113041
Drug: abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab with low-dose weight-adjusted heparin
Study: 9671000
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with standard-dose, weight-adjusted heparin
Study: 2673441
Drug: Calcium carbimide
Normalized name: calcium carbimide
DrugBank: Calcium carbimide (DB09116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbimide (CC)
Study: 1103576
Drug: Clonidine (rapidly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (rapidly falling dosage)
Study: 31270800
Drug: Inhaled aerosolised
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aerosolised prostacyclin (20 ng/kg/min)
Study: 31270800
Drug: Inhaled saline
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled saline (NaCl, 9 mg/mL)
Study: 28911799
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol proprionate (CP)
Study: 28911799
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone diproprionate (BDP)
Study: 23955418
Drug: Venlafaxine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (150 mg/day)
Study: 23955418
Drug: Pregabalin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (200 mg/day)
Study: 17131249
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% eye drops twice daily
Study: 17131249
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate eye drops twice daily
Study: 15590250
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine (0.05 mg) with mepivacaine (100 mg)
Study: 15590250
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine (0.1 mg) with mepivacaine (100 mg)
Study: 15590250
Drug: Epidural neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural neostigmine (0.15 mg) with mepivacaine (100 mg)